Drs. Wassim Mchayleh & Komal Jhaveri Discuss the evERA Trial in ER+ Metastatic Breast Cancer

Drs. Wassim Mchayleh and Komal Jhaveri review the evERA trial, which evaluated the oral SERD giredestrant combined with everolimus versus standard endocrine therapy with everolimus in ER-positive metastatic breast cancer. The study demonstrated improved progression-free survival across key subgroups, including patients with and without ESR1 mutations. They also discuss how clinicians may approach second-line treatment decisions, weighing combinations such as SERDs with abemaciclib or everolimus, while considering toxicity profiles, resistance mechanisms like RB1 mutations, and the role of next-generation sequencing in guiding therapy. Sponsored By Gilead.